- Home
- MESO
MESO
Mesoblast Limited
as 07-26-2024 4:00pm EST
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
| Founded: | 2004 | Country: | Australia |
| Employees: | N/A | City: | N/A |
| Market Cap: | 861.6M | IPO Year: | N/A |
| Target Price: | $8.50 | AVG Volume (30 days): | 223.3K |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $8.66 | Next Earning Date: | 08-28-2024 |
| Revenue: | $7,253,000 | Revenue Growth: | -10.69% |
| Revenue Growth (this year): | -13.76% | Revenue Growth (next year): | 71.31% |
Latest Mesoblast Limited News
MESO Breaking Stock News: Dive into MESO Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 days ago
FDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapy
MT Newswires
4 days ago
Mesoblast Says FDA Accepted Resubmitted Biologics License Application for Ryoncil; Shares Rise Pre-Bell
GlobeNewswire
4 days ago
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
Clinical Trials Arena
5 days ago
Mesoblast begins subject enrolment in Phase III back pain treatment trial
GlobeNewswire
5 days ago
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
Simply Wall St.
16 days ago
July 2024 ASX Leaders With High Insider Ownership And Strong Growth Prospects
Simply Wall St.
16 days ago
Insider-Owned ASX Growth Companies To Watch In July 2024
MT Newswires
18 days ago
Mesoblast Resubmits Ryoncil Biologics License Application
Compare MESO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MESO Mesoblast Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.